Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Labors Of Califf

Executive Summary

The US FDA Commissioner nominee Robert Califf has so far promised to revamp FDA’s opioids policy, stay away from industry after leaving the agency, and clean up Accelerated Approval in 30 days. What other tasks will Democratic Senators demand before granting him confirmation?

You may also be interested in...



Califf Limps Toward FDA Commissioner Confirmation

Final Senate vote on Robert Califf’s nomination to lead the US Food and Drug Administration is expected 15 February after Califf narrowly squeaked through a procedural vote. The final vote is expected to be even tighter.

Sen. Wyden Using Califf Nomination To Extract Accelerated Approval Reforms

The unexpectedly tight fight to get Robert Califf confirmed as FDA commissioner is giving lawmakers additional leverage to extract commitments. However, the Senate Finance Chair may be overestimating FDA’s ability to swiftly pull accelerated approvals without new legislation.

US FDA Commissioner: The Waiting Game Continues

The wait for a permanent head of the FDA is continuing into the second year of the Biden Administration. One message is coming through loud and clear: the agency is clearly not a top priority for the White House ... and that might just be a good thing.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel